Indivior Pharmaceuticals Inc
Market Cap
$3.91B
P/E Ratio
19.10
EPS
$1.64
Dividend Yield
0.00%
52-Week Range
$8.64 — $38.00
Volume
2.92M
Avg Volume
2.54M
Beta
1.19
P/E (TTM)
19.10
Forward P/E
10.13
PEG Ratio
0.69
P/S (TTM)
3.28
P/B (TTM)
-41.58
P/FCF
-48.30
EV/EBITDA
57.35x
EV/Sales
—
ROE (TTM)
-0.99%
ROA (TTM)
0.17%
ROIC
0.10%
Gross Margin
0.80%
Operating Margin
0.24%
Net Margin
0.13%
Debt/Equity
-3.58
Current Ratio
0.71
EPS Growth (YoY)
+10.10%
Revenue Growth (YoY)
+0.08%
EPS Growth (3Y)
-0.06%
EPS Growth (5Y)
-0.01%
Sales Growth (3Y)
+0.15%
Sales Growth (5Y)
+0.10%
EPS Est (This Year)
$3.09
EPS Est (Next Year)
$3.44
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$1.56
Buy
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $43.75(39.6% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
124.77M
Float
120.66M
Free Float %
96.71%
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
NASDAQ
IPO Date
2014-12-29
Employees
1030
CEO
Joseph J. Ciaffoni
Index Membership
—
Website
https://www.indivior.com
Indivior Pharmaceuticals Inc (INDV) is a healthcare company in the drug manufacturers - specialty & generic industry listed on the NASDAQ. With a market capitalization of $3.91B, a P/E ratio of 19.10, INDV is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare INDV against other stocks using dozens of fundamental and technical filters.
Indivior Pharmaceuticals Inc (INDV) has a trailing twelve-month (TTM) P/E ratio of 19.10. This is near the market average range. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Indivior Pharmaceuticals Inc (INDV) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Indivior Pharmaceuticals Inc (INDV) has a market capitalization of $3.91 billion, classifying it as a mid-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Buy" rating on Indivior Pharmaceuticals Inc (INDV) with an average score of 2.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $43.75 implies 39.6% upside from the current price.